1. Benefit–risk balance and its individual determinants with personalised chronic obstructive pulmonary disease (COPD) treatment choices.
Benefit–risk balance and its individual determinants with personalised chronic obstructive pulmonary disease (COPD) treatment choices. When a clinician is deciding which pharmacological treatment options to prescribe to a patient, they have to consider expected benefits (determined by individual presentation and underlying mechanisms of disease) and possible risks (which depend on individual risk factors and comorbidities). LABA: long-acting β2 agonists; LAMA: long-acting muscarinic antagonists; ICS: inhaled corticosteroids. Reproduced from [6] with permission from the publisher.
Venkataramana K. Sidhaye et al. Eur Respir Rev 2018;27:180022
©2018 by European Respiratory Society